United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 11,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 11,000 shares of the firm’s stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $450.34, for a total transaction of $4,953,740.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $16,563,955.54. This represents a 23.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Down 0.4%

Shares of NASDAQ:UTHR opened at $453.53 on Friday. The company has a market cap of $20.46 billion, a PE ratio of 17.19, a P/E/G ratio of 4.96 and a beta of 0.66. The company’s 50-day moving average price is $407.40 and its 200 day moving average price is $336.86. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $479.50.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.39 EPS. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday. Bank of America boosted their target price on United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a report on Tuesday, September 2nd. Oppenheimer boosted their target price on United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Finally, UBS Group boosted their price objective on United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Seven analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $483.73.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Strs Ohio raised its position in United Therapeutics by 847.5% during the third quarter. Strs Ohio now owns 10,062 shares of the biotechnology company’s stock valued at $4,218,000 after buying an additional 9,000 shares during the period. Emerald Mutual Fund Advisers Trust increased its holdings in shares of United Therapeutics by 112.2% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 5,474 shares of the biotechnology company’s stock valued at $2,295,000 after purchasing an additional 2,894 shares during the period. Rakuten Investment Management Inc. acquired a new position in shares of United Therapeutics in the 3rd quarter valued at about $1,823,000. Seizert Capital Partners LLC increased its stake in United Therapeutics by 17.1% in the 3rd quarter. Seizert Capital Partners LLC now owns 146,991 shares of the biotechnology company’s stock valued at $61,620,000 after buying an additional 21,450 shares during the period. Finally, Root Financial Partners LLC acquired a new position in United Therapeutics in the 3rd quarter valued at approximately $51,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.